Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EBITDA (2016 - 2026)

Rockwell Medical filings provide 16 years of EBITDA readings, the most recent being -$398000.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 23.31% to -$398000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.7 million, a 871.55% decrease, with the full-year FY2025 number at -$4.7 million, down 871.55% from a year prior.
  • EBITDA hit -$398000.0 in Q4 2025 for Rockwell Medical, up from -$1.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $1.9 million in Q3 2024 to a low of -$8.4 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$1.7 million (2023), compared with a mean of -$2.9 million.
  • Biggest five-year swings in EBITDA: soared 211.46% in 2024 and later crashed 361.94% in 2025.
  • Rockwell Medical's EBITDA stood at -$8.4 million in 2021, then skyrocketed by 76.48% to -$2.0 million in 2022, then surged by 72.18% to -$547000.0 in 2023, then rose by 5.12% to -$519000.0 in 2024, then rose by 23.31% to -$398000.0 in 2025.
  • The last three reported values for EBITDA were -$398000.0 (Q4 2025), -$1.6 million (Q3 2025), and -$1.3 million (Q2 2025) per Business Quant data.